INTRODUCTION
Recommended doses of a drug are based on efficacy and safety considerations. It is common for efficacy as well as toxicity (as measured by adverse reactions and side effects) to increase over the range of doses, although at higher doses the efficacy may show a plateau or even a decline. These considerations lead one to define a minimum effective dose (MINED) and a maximum safe dose (MAXSD). The range delimited by these two doses is called a therapeutic window, which consists of doses that are both effective and safe. We address the problem of identifying the therapeutic window by finding the MINED and MAXSD simultaneously. Our approach is similar to that of Tamhane, Hochberg, and Dunnett (1996) , who considered the problem of finding the MINED, and of Tamhane, Dunnett, Green, and Wetherington (2001), who considered the problem of finding the MAXSD. Simultaneous tests on efficacy and safety endpoints have been previously studied by Turri and Stein (1986) , Thall and Russell (1998) , Thall and Cheng (1999) , and Jennison and Turbull (1993) .
The applicability of this article is limited to settings where efficacy and safety are evaluated in the same study using predetermined continuous endpoints. Generally, efficacy is evaluated at phase II/III, whereas safety is evaluated at all phases. Typically, efficacy endpoints are predetermined, whereas some safety endpoints may be unanticipated (e.g., rare adverse events). Also, many safety endpoints are of ordinal or count type. Statistics different than the t-statistics on which the procedures proposed in this article are based must be used for such data.
Large values of the ,ui relative to /uo represent high efficacy, whereas large values of the T7i relative to 70 represent high toxicity. Let 8~ > 0 and 82 > 0 be two specified threshold constants for efficacy and toxicity. Any dose i with /,u > /,q + 8, is regarded as effective, and any dose j with r1j < rQO + 82 is regarded as safe. The true MINED and MAXSD are defined as for i, j = 1, 2, . . , k. Here the random vector (U1, U2, .... Uk; V1, V2, ..., Vk) has a joint 2k-variate normal distribution with zero means, unit variances, and correlation structure corr(Ui, Uj) = corr(Vi, Vj) = yi (say) ni + k=AAnj+ for i j, -(ni+no)(nj,+no) = i fori j, 
This assumption is weaker than the strong monotonicity assumption tLo < ,L < l < I and 710 < 7l7 < . < 77k, with at least one strict inequality in each case.
The goal is to estimate the MINED and MAXSD with the following probability requirement. Let MINED and MAXSD be the dose levels estimated as the MINED and MAXSD. Then we want P{MINED < MINED or MAXSD > MAXSD} = P{an ineffective dose declared effective or an unsafe dose declared safe} < a,
where a is specified. If MINED or MAXSD does not exist, then we conclude that MINED > k or MAXSD < 1. If MINED > MAXSD, then no therapeutic window is found.
A NEW MULTIVARIATE t-DISTRIBUTION
Denote by xi and iy(i = 0, 1, .., k) the sample means, and 
where r, = {yi} for 1 < i,j < ?, 2 = {yij} for m i, j < k, F12 = {7,j} for 1 < i < e and m < j < k, and Fr2 denotes the transpose of Fr2. Dependence of Fr, F2, and Fl2 on 1 . . , and m, .., k is suppressed for notational convenience. Note that for t =k and m= 1, Fl =F2 = F = F. We denote the required upper a critical point by g,(t, km + 1,v, F2, F12, , p), which is the solution in g to the equation -m + 1, v, F,) . Similarly, if mn = k + 1, then g,(e, 0, v, F, F2, F12, p) equals h,(e, v, F ). Note that these two critical points do not depend on Fr2 and p.
To obtain an expression for the probability in (8), we first condition on (Wl, W2). The joint probability density function (pdf) f,(wl, w2) of (Wl, W2) was derived in earlier work (Tamhane and Logan 2000) using the Wishart distribution. Then by exploiting the product correlation structure (5), and a result from Bechhofer and Tamhane (1974) In the foregoing, (( ) is the standard normal cumulative distribution function (cdf), and D2 (., I -p) the cdf of the standard bivariate normal distribution with correlation coefficient -PEvaluation of (9) requires four-variate integration. However, the main difficulty is that the solution g, (, km+ 1, v, F, r2, r12, p) depends on the unknown p. As an approximation, one could use a pooled (from all dose groups) sample estimate of p. However, it turns out that the solution is relatively insensitive to p, as calculations for gt(k, k, v, y, p) for k = 2(1)5, v = oo, y = 1/2 and p = .1(.2).7 given in Table 1 show. This suggests that the Bonferroni upper bound on this critical constant, which does not require knowledge of p, would provide a good approximation. This upper bound is hl/2(k, v, y), which satisfies the equation The last row of 
NORMAL THEORY PROCEDURES

Preliminaries
The hypotheses for demonstrating efficacy are Hi():
where HM') states that the ith dose is ineffective. Similarly, the hypotheses for demonstrating safety are 
Test Procedures for Family Y
A simple but conservative way to control the FWE for . at level a is to control the FWE for T and 52 separately at level a/2 and use the Bonferroni inequality. More generally, different levels ac and a2 (where ac + a2 = a) may be used for , and 2 to reflect different weights that one may wish to attach to efficacy testing and safety testing. We call the Bonferroni procedures approximate, and call those based on the exact critical constants exact.
Step-Down Test Procedures
We omit the discussion of the exact and approximate singlestep ( 
Although this exact procedure is not implementable because it requires knowledge of p, we still present it here, because its bootstrap version is implementable. It operates as follows.
Initialize e = k, m = 1 and Fl = F2= F2 = F.
General
Step This test procedure is shown graphically in Figure 1 . Notice that an advantage of testing the efficacy and safety hypotheses jointly is that whenever an intersection hypothesis He l)n H2) is rejected, then even if one of the component hypotheses is not rejected, that component hypothesis remains in contention as a candidate for rejection at a later step. This is not the case when the efficacy and safety hypotheses are tested separately using the approximate Bonferroni method, where testing stops once a given hypothesis is not rejected. 
BOOTSTRAP PROCEDURES
Normal theory methods require the strong distributional assumption of bivariate normality. Furthermore, they assume homoscedasticity across dose groups and common correlation. Bootstrapping allows for relaxation of these restrictive assumptions. However, there is no unique way to apply bootstrapping, and it is not always a priori clear which method works better. The bootstrap procedures given here have been tested extensively via simulation. They assume homoscedasticity and common correlation because they pool the data across different dose groups; however, they can be easily modified by not pooling. They approximately account for the unknown correlation through resampling.
The bootstrap versions of SD1 and SD2 are as follows: Note that we do not use the full shortcut version of SD1 (as given in Sec. 4.3.2) in the bootstrap procedure, because such a shortcut requires computing the adjusted p values for each t ) for 1 < i < f and t(2) form < j k instead of just for maxl<i<e t(l) and maxj (2) Therefore, the full shortcut version of SD1 results in more computational effort in general, when implemented using the bootstrap. Also note that the p values calculated earlier are bootstrap estimates of the multiplicity adjusted p values. They are not monotonically adjusted for stepdown testing, because the p value for any hypothesis is calculated only if the p value for its implying hypothesis is less than a. 4. Exact SD2 procedure. The bootstrap SD2 procedure is similar to the SD1 procedure, except that no maximums are taken over the t-statistics when calculating the estimates of the adjusted p values.
EXAMPLE
A pharmaceutical company performed a phase II randomized double-blind, placebo-controlled parallel group clinical trial of a new drug for the treatment of arthritis of the knee using four increasing doses (labeled 1, 2, 3, and 4). A total of 370 patients were randomized to the five treatment groups. Several efficacy and safety endpoints were measured on each patient at the baseline and at the end of the study after 4 weeks. Here we consider the changes from the baseline in one particular efficacy and one safety endpoint.
For proprietary reasons, the actual data are concealed by contaminating them with normally distributed random errors with zero mean and one-tenth of the standard deviation of the original data. This slightly increases the standard deviations of the efficacy and safety variables for each dose group and reduces the correlations between them. As a further step to comply with the company requirements, the identity of the safety variable is not revealed, and its values are coded postcontamination. Despite these measures, the essential statistical characteristics of the data are unimpaired, and the example remains valuable for illustrating the proposed procedures.
The efficacy variable is the pooled WOMAC (Western Ontario and McMaster Universities osteoarthritis index) score, a composite score computed from assessments of pain (5 items), stiffness (2 items), and physical function (17 items). The composite score is normalized to a scale of 0-10. An increase in WOMAC indicates an improvement in disease condition. For the purpose of this example, an average improvement by .5 units compared to the zero dose control is regarded as clinically significant.
The safety variable is the serum level of a certain chemical, labeled as Z. As dose level increases, the serum level of Z is expected to increase from the baseline to the end of the study. For the purpose of this example, an increase in serum level of Z by 3 mmol/L over the zero dose control is regarded as clinically significant. The summary data for the two variables are given in Table 2 . Normal plots of the data were made and found to be quite satisfactory. The sample sizes are nearly equal, and so yij 1/2. Box's (1949) test for homogeneity of covariance matrices yielded F = 1.705 with p value = .059, which is borderline nonsignificant. The Bartlett and Levene tests for homogeneity of variances yielded highly nonsignificant results. Therefore, all the assumptions are satisfied for the normal theory procedures. It is of interest to note that the correlations are all close to zero.
The pooled estimates of the standard deviations for WOMAC (the efficacy variable) and Z (the safety variable) are 6-= 1.962 and r = 2.210, each with 365 I oo df. The ANOVA F-statistics for WOMAC and Z equal 5.079 (p = .001) and 9.747 (p = .000). The t-statistics for WOMAC and Z are computed using (12) with 86 = .5 and 82 = 3 and are given in Table 3 .
Approximate SD1 Procedure
The critical constants ho25(i, v = oo, y = 1/2) for i 1,2,3,4 equal 1.960, 2.212, 2.349, and 2.442. A straightforward application of SD1 at the .025-level separately on WOMAC and Z yields MINED = 3 and MAXSD > 4 (i.e., all four doses are safe). Thus the lower end of the therapeutic window is dose 3, whereas the upper end can be higher than dose 4.
Approximate SD2 Procedure
In this case, each t-statistic is compared with the same critical constant, t.025( = oo) = 1.960, in a step-down manner starting with dose 4 for WOMAC and dose 1 for Z. Because tl) = 1.729 < 1.960, the procedure stops with the conclusion that MINED > 4 (i.e., none of the doses are effective). Also, 
Simulation Results
Simulated overall powers for approximate normal theory SD1 and SD2 and their bootstrap versions are summarized in Table 5 for normal data. The type I FWEs of the procedures are not reported because they were found to be well controlled at or below the .05 level for both normal and nonnormal data. Biases in the estimates MINED and MAXSD or, equivalently, the corresponding marginal powers show similar relative patterns as the overall powers and hence are not reported either (see Tamhane and Logan 2000) .
First, we note that SD1 is more powerful (by about 11%-12%) than SD2 for step configurations, but less powerful (by about 6%-8%) for linear configurations. The higher power of SD1 for step configurations is explained by the fact that in this configuration, dose 2 (which is the MINED) through dose 5 have the same mean for efficacy. As a result, the corresponding sample means are likely to be nonmonotone. When test- Because the dose means are monotone for linear configurations (and much higher at higher doses than the mean for the MINED, e.g., /u5 = 5 >> 22 = 2), SD2 often does not stop testing early due to nonsignificance and thus gains in power. SD1 also gains in power due to larger differences between the means at higher doses and the MINED mean, but not as much, because it uses a larger critical constant. Therefore, SD2 is more powerful than SD1 for linear configurations.
Comparing SD1 and SD2 normal theory procedures with the corresponding bootstrap procedures, we find that the latter are always more powerful. The gain in power for the bootstrap SD1 over the normal theory SD1 is about 3%-5%, whereas the corresponding gain for SD2 is only around 1%. It may appear surprising that the bootstrap procedures are more powerful than the normal theory procedures when the data are normal. The explanation is that although the bootstrap procedures may suffer slight loss in power because they do not exploit normality, this loss is more than compensated for by their use of joint testing of efficacy and safety, as illustrated in Figure 1 . On the other hand, the approximate normal theory procedures treat the two endpoints as separate and use the Bonferroni approximation.
CONCLUDING REMARKS
The bootstrap procedures not only are more robust with regard to distributional assumptions, but also are more powerful because of their joint testing feature. Therefore, they are recommended. However, they are more complicated to implement and explain, and require special software. Also, their FWE control is only approximately guaranteed for small samples. For step configurations, bootstrap SD1 has a power advantage of about 14% over bootstrap SD2, whereas for linear configurations, bootstrap SD2 has a power advantage of about 5%. The true dose mean configuration is of course unknown. Although one might argue that a linear configuration is more likely than a step configuration, a flat response beyond a certain dose level is in fact more commonly observed than might be expected, especially for efficacy. The reason is that in the dose selection process, it is usually difficult to find the right doses to test, and practitioners tend to select doses at the plateau of the dose-response curve. If the efficacy response function has a downturn at higher doses, then SD2 will have very low power. Given that the power gain of SD1 over SD2 for step configurations is much greater than its power loss for linear configuration, we recommend bootstrap SD1 as a general procedure unless dose response is known to be roughly linear (or at least strictly increasing).
We have assumed weak monotonicity (2). If strong monotonicity can be assumed, then more powerful procedures can be developed based on the isotonic estimates (Robertson, Wright, and Dykstra 1988) of the /i and the ri. The exact distribution theory would be quite complicated, but the bootstrap version should be relatively straightforward.
Some may argue that efficacy is more important than safety, and so a dose need not be tested for safety unless it is proven 
